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Aims Duchenne muscular dystrophy (DMD), a degenerative pathology of skeletal muscle, also induces cardiac failure and
arrhythmias due to amutation leading to the lack of the protein dystrophin. In cardiac cells, the subsarcolemmal localiza-
tion of dystrophin is thought to protect the membrane frommechanical stress. The absence of dystrophin results in an
elevated stress-inducedCa2+ influxdue to the inadequate functioning of several proteins, such as stretch-activated chan-
nels (SACs). Our aim was to investigate whether transient receptor potential vanilloid channels type 2 (TRPV2) form
subunits of the dysregulated SACs in cardiac dystrophy.
Methods
and results
We defined the role of TRPV2 channels in the abnormal Ca2+ influx of cardiomyocytes isolated from dystrophic mdx
mice, an established animal model forDMD. In dystrophic cells, western blotting showed that TRPV2was two-fold over-
expressed.While normally localized intracellularly, inmyocytes frommdxmiceTRPV2channelswere translocated to the
sarcolemma andwereprominent along theT-tubules, as indicated by immunocytochemistry.Membrane localizationwas
confirmed by biotinylation assays. Furthermore, in mdx myocytes pharmacological modulators suggested an abnormal
activity of TRPV2, which has a unique pharmacological profile among TRP channels. Confocal imaging showed that
these compounds protected the cells from stress-induced abnormal Ca2+ signals. The involvement of TRPV2 in these
signals was confirmed by specific pore-blocking antibodies and by small-interfering RNA ablation of TRPV2.
Conclusion Together, these results establish the involvement of TRPV2 in a stretch-activated calcium influx pathway in dystrophic
cardiomyopathy, contributing to the defective cellular Ca2+ handling in this disease.
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1. Introduction
Duchenne muscular dystrophy (DMD) is a X-linked degenerative path-
ology of skeletal muscle, affecting 1 in 3500male births. Initially, this pro-
gressive disease causes muscle weakness and an impaired mobility
requiring a wheelchair by 8–12 years of age. Subsequently, DMD is re-
sponsible for the slow development of respiratory failure. Medical
advances, such as therapies for respiration support, have prolonged
the life expectancy of patients to around 25 years. However, cardiac
muscle manifestations are present in essentially all patients by 20 years
of age. The heart develops a dilated cardiomyopathy (DCM) resulting
in cardiac failure and arrhythmias causing the death of 20% of all
patients.1
DMD results from a mutation in the Dys gene located on the X
chromosome. This genetic alteration is responsible for the absence of
the protein dystrophin.2 Dystrophin is a rod-shaped protein expressed
in muscle fibres. In cardiomyocytes, its subsarcolemmal and sarcomeric
localization along the T-tubule network is essential to maintain the
membrane architecture.3 Dystrophin is associated with the dystrophin-
glycoprotein complex (DGC) which is composed of several transmem-
brane proteins such asa-,b-dystroglycans anda-,b-, g-, d-sarcoglycans
and sarcospans. These proteins provide a mechanical link between the
extracellular matrix, via laminin binding, and the cytoskeleton, via
F-actin binding.4 This molecular bridge is thought to preserve the mem-
brane integrity during mechanical stress.5 The DGC is also involved in
the maintenance of the normal cellular Ca2+ gradient via the regulation
of several proteins.6,7 In general, the absence of dystrophin increases the
membrane fragility, either directly or indirectly. This can be determined
with a variety of experimental techniques and is often detected as an
elevated stress-induced Ca2+ influx from the extracellular space.8
Generally, two distinct Ca2+ influx pathways have been considered,
both in skeletal muscle fibres and in cardiomyocytes. (i) Localized
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microruptures of the sarcolemma result in abnormal stress-induced
entry of Ca2+ (and other ions) into the cells.9,10 (ii) As mentioned
above, loss of dystrophin seems to be responsible for the dysregulation
of a number of proteins, such as stretch-activated channels (SACs),
which constitute an alternative pathway for Ca2+ entry into myo-
cytes.11,12 SACs are non-selective cation channels with an increased ac-
tivity triggered by mechanical stress.13,14
At present, the molecular identity of SACs is not known, and most
likely there are several types of SACs expressed in skeletal and cardiac
muscle. Some of the SACs are thought to contain ion channel proteins
from the large family of transient receptor potential (TRP) channels,
such as TRPV2 or TRPC1. Since preventing abnormal Ca2+ influx via
SACs could be a strategy to ameliorate dystrophy (and other diseases),
there is considerable interest in the molecular underpinnings and func-
tioning of these channels.
In addition to enlarged sarcolemmal Ca2+ influx, it has been observed
that in dystrophic cardiomyocytes, the entire Ca2+ signalling system, in
particular the Ca2+-induced Ca2+ release mechanism, shows an abnor-
mal susceptibility to generate exaggerated Ca2+ signals, such as Ca2+
sparks andCa2+waves.15 This seems to result, at least partly, frompost-
translationalmodifications of the SRCa2+ release channels (a.k.a. ryano-
dine receptors, RyRs). As a consequence of all these Ca2+ signalling dis-
turbances, the resting cytosolic concentration was found to be slightly
elevated in dystrophic cardiomyocytes.13
In thepresent study,weexaminedwhether the transient receptor po-
tential vanilloid type 2 channels (TRPV2) form part of a SAC responsible
for the abnormal Ca2+ influx in dystrophic ventricular cardiomyocytes
frommdxmice, an established animalmodel forDMD.TheTRPV2over-
expression and specific re-localization to the sarcolemma and along the
T-tubule network, highlighted by western blot analysis and immuno-
cytochemistry, show a mobilization of this protein in dystrophic cardio-
myocytes. The combination of relatively unspecific pharmacological
interventions with specific functional experiments involving pore-
blocking antibodies and small-interfering RNA (siRNA)-mediated abla-
tion of the protein indicate an abnormal TRPV2 activity in dystrophic
cardiomyocytes. Together these results suggest the involvement of
TRPV2 as a stretch-activated Ca2+ influx pathway in dystrophic cardio-
myocytes, presumably contributing to the defective cellular Ca2+ hand-
ling in these cells.
2. Methods
2.1 Cell isolation
All animal procedures conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health and
National Research Council of the National Academy of Sciences (NIH
Publication No. 85-23, revised 2011), to the Swiss Animal Protection Law
(TSchG), and were carried out with permission by local Swiss authorities
(permit BE126/12). C57BL/10mice (4months old), in the following referred
to as wild type (WT), and C57BL/10ScScn-mdx mice of identical age were
provided by Profs M. Ru¨egg (University Basel, Switzerland) and U. Ru¨egg
(University Geneva, Switzerland) or purchased from Jackson Laboratory.
Animals were euthanized by cervical dislocation, followed by rapid
removal and enzymatic dissociation of the cardiac tissue as previously
described.16
2.2 Immunocytochemistry
Cardiomyocytes were fixed with 4% paraformaldehyde in PBS for 1 h and
permeabilized with 0.5% Triton X-100 in PBS for 1 h at room temperature.
A blocking solution of 4% BSA was applied for 1 h. Cells were incubated
overnight at 48C in a wet chamber with an anti-TRPV2 antibody against an
extracellular epitope (1/100; Alomone ACC-039) and an anti-NCX anti-
body (1/100; Thermo Scientific MA3-926) diluted in PBS 4%, BSA, and
0.5% Triton X-100. After washing out in PBS, cells were incubated for 2 h
in PBS 4% BSA and 0.5% Triton X-100 with secondary antibodies (Alexa
Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 568-conjugated
donkey anti-mouse IgG; 1/100).
2.3 Experimental solutions
The isotonic superfusion solution contained (in mM): 140NaCl, 5.4 KCl, 1.8
CaCl2, 1.1 MgCl2, 5 HEPES, and 10 glucose. The osmolarity was 310mOsm,
and pH 7.3. The hypotonic solution contained (inmM): 70NaCl, 5.4 KCl, 1.8
CaCl2, 1.1 MgCl2, 5 HEPES, and 10 glucose, and had an osmolarity of 170
mOsm. SKF96365, tranilast, ruthenium red, ryanodine, and thapsigargin
were added for at least 30 min before the experiment. The PBS contained
(inmM): 130NaCl, 2.07 KCl, 1.5Na2HPO4, and 8 KH2PO4; pHwas adjusted
to 7.4 with NaOH.
Most chemicals were obtained from Sigma. Collagenase (type II) was
purchased from Worthington, Di-8ANEPPS and fluo-3-AM from Biotium,
tranilast from Cayman, thapsigargin and ryanodine from Alomone,
2-aminoethyl diphenylborinate (2-APB) and ruthenium red (RuR) from
Fluka, and TRPV2 and TRPC1 antibodies from Alomone (ACC-039 and
ACC-032 for TRPV2 and ACC-118 for TRPC1). All experiments were per-
formed at room temperature (208C).
2.4 Confocal microscopy
Examination of immunolabelled samples and Ca2+ imaging were performed
on an inverted laser scanning confocal microscope (Olympus FV-1000) with
a ×60 water immersion objective (NA, 1.2). Cells were loaded with
fluo-3-AM (5 mM) for 30 min and excited at 473 nm to record the fluores-
cence between 490 and 590 nm. Amplitude (F/F0) and time course of Ca
2+
transients were computed using ImageJ and Igor Pro software.
To label T-tubules, ventricular myocytes were incubated with 10 mM
di-8-ANEPPS for 30 min.12 After staining, the images of living cells were
acquired with the confocal system.
2.5 Western blot
Proteins were extracted from isolated ventricular cardiomyocytes using
NP40 cell lysis buffer (Invitrogen) supplemented with a protease inhibi-
tor cocktail. Protein extracts were dosed using BCA protein assay kit
(Thermo scientific) at 562 nm and then divided into samples and denatured
by incubation in Laemmli buffer (Sigma) for 10 min at 958C. Subsequently,
samples were subjected to SDS–PAGE and western blot analysis. The
blots were incubated with anti-TRPV2 against an extracellular epitope
(1/200; Alomone ACC-039) and anti-actin (1/1000) antibodies overnight
at 48C and then with horseradish peroxidase (HRP)-conjugated secondary
anti-rabbit and anti-mouse (1/10000, Jackson) antibodies for 1 h at room
temperature. Finally, the blots were developed with enhanced chemilumin-
escent substrates for detection of HRP enzymatic activity (Thermo scientif-
ic). The apparent molecular weights were estimated according to the
position of prestained protein markers (Precision plus protein standards;
Bio-Rad).
2.6 Biotinylation
Isolated cardiomyocytes were incubated with biotinylation reagent
(Sulfo-NHS-LC-Biotin, APExBIO, 0.5 mg/mL in PBS) at 378C for 2 h. The
biotin reagent was removed and cells were washed two times in cold PBS
with 100 mM glycine and two times in cold PBS alone. Then, lysates were
prepared and dosed as described above. One hundred micrograms of
each samples were incubated with 100 mL of streptavidin agarose resin
(Thermo Scientific) for 16 h at 48C to capture biotinylated proteins.
The beads were pelleted and washed in lysis buffer. Captured proteins
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were eluted at 608C for 30 min with Laemmli 2X sample buffer containing
40 mg/mL of dithiothreitol. Then they were analysed by western blot as
described above with primary antibodies: anti-TRPV2 against an extracellu-
lar epitope (Alomone ACC-039, 1/100), anti-GAPDH (positive control,
Fitzgerald, 1/3000), and anti-P44/P42MAPK (negative control, Cell Signaling,
1/2000).
2.7 Cardiomyocyte culture and transfection
Isolated cardiomyocyteswere cultured inDMEM supplementedwith insulin
(10 mg/mL), HEPES (10 mM), NaHCO3 (4 mM), blebbistatin (25 mM), and
cytochalasin D (0.5 mM). TRPV2 siRNA and non-targeting siRNA were
obtained fromOrigene. Transfection of siRNAwas performed using Gene-
Silencer (Genlantis) for 4 h. Subsequently, this medium was replaced by so-
lution without transfection reagent for 20 h. Lysates were prepared and
dosed as described above.
2.8 Real-time PCR
Total RNA fromsiRNAagainstTRPV2and scrambled siRNAdystrophic car-
diomyocytes were extracted using RNA purification kit (NucleoSpin RNA,
Macherey-Nagel). Mm_Trpv2_1_SG and Mm_Actb_1_SG were used as
specific mouse RT–PCR primers (Qiagen). The ACTB housekeeping gene
(against b-actin) and TRPV2 gene were amplified in parallel. Real-time
RT–PCR was performed using 9 ng/mL of RNA (KAPA SYBR FAST
One-Step Universal Kit) and 200 nM of each primer in a total reaction
volumeof 15 mL.Datawere recordedonanEcoReal-TimePCRsystem(Illu-
mina Labgene Scientific SA), and cycle threshold (Ct) values for each reac-
tion were determined using analytical software from the same
manufacturer. Each cDNA was amplified in duplicate, and Ct values were
averaged for each duplicate. The average Ct value for ACTB was subtracted
from the average Ct value for the gene of interest. As amplification efficien-
cies of TRPV2 genes and ACTB were comparable, the relation 22DCt gave
the amount of mRNA, normalized by ACTB.
2.9 Statistical analysis
All results are expressedasmean+ SEMof nobservations. Sets of datawere
compared using Student’s t-test, and significance is denoted as *P, 0.05,
**P, 0.01. N refers to number of animals, n to number of cells.
3. Results
3.1 Osmotic stress induces abnormal Ca21
signals in dystrophic cardiomyocytes
As reported before, dystrophic muscle cells exhibit an abnormal mem-
brane fragility and increased stretch sensitivity.5,17 We applied mild
osmotic shocks to WT and dystrophic cardiomyocytes mimicking fea-
tures of mechanical membrane stress during contractions (cell swelling
by 15.8% in both, WT and mdxmyocytes).15 After 30-min loading with
the fluorescentCa2+ indicator fluo-3-AM,myocyteswere briefly super-
fused with a mildly hypotonic solution (40 s). The fluorescence was
recorded to measure Ca2+ signals before, during, and after the
osmotic stress, visible as a transient decrease of fluorescence due to
dye dilution (Figure 1A and B). As described in previous studies,15 cardi-
omyocytes frommdxmice displayed an increased fluorescence starting
after a mild osmotic stress (Figure 1B). For quantitative analysis, we aver-
aged the normalized fluorescence during a 40-s time window after the
osmotic stress (Figure 1C, left). While in WT cells the fluo-3 signal
returned to baseline after the stress (F/F0: 0.98+ 0.02, n ¼ 10), the
Ca2+-related fluorescence observed in mdx cardiomyocytes was
1.4-fold larger (F/F0: 1.41+0.09, n ¼ 13). Besides an abnormally large
transsarcolemmal Ca2+ influx, a different extent of Ca2+ loading of
the sarcoplasmic reticulum (SR) and/or an elevated sensitivity of the
SR Ca2+ release mechanism could explain these increased Ca2+
signals, similar to other pathologies with altered SR function.16,18
However, applying rapid puffs of caffeine-containing solutions to esti-
mate the Ca2+ SR content before and after the osmotic shock did not
reveal a difference between dystrophic and WT cells (Figure 1C, right).
But the mdx cells lost significantly more Ca2+ than the WT myocytes,
as one would expect because of their exaggerated Ca2+ signals. As it
has been reported before, the excessive cytosolic Ca2+ signals in mdx
cardiomyocytes observed here are triggered, at least partly, by Ca2+
influx via several pathways such as local microruptures in the sarco-
lemma and the abnormal activation of SACs.9,12,19 The molecular iden-
tity of SACs is not yet established, but for quite some time, TRP channels
have been suspected to play a role.19 Recently, TRPV2 channels have
been proposed to be part of these SACs in dystrophic skeletal muscle
fibres.17,20 Therefore, we next carried out experiments to define the
role of TRPV2 channels in the abnormal stress-induced Ca2+ signals in
dystrophic cardiomyocytes.
3.2 Sarcolemmal TRPV2 localization and
overexpression in mdx cardiomyocytes
In cultured dystrophic skeletal muscle myotubes, TRPV2 channels were
found tobe localized to the sarcolemma,where theymediatedabnormal
Ca2+ influx from the extracellular space.7,17 In physiological conditions,
TRPV2 channels are mainly localized to intracellular membrane struc-
tures, but they are known to translocate to the plasma membrane
upon specific stimulation, such as by insulin growth factor-1 (IGF-1).
Once activated, they participate in the function and structure of cardio-
myocytes.21,22 Therefore, we compared the TRPV2 expression and its
subcellular distribution in freshly isolatedWT andmdx cardiomyocytes
(Figure 2). Comparative TRPV2 immunocytochemistry in WT cardio-
myocytes showed only a staining within the cell (Figure 2A, left above).
In contrast, in mdx cells, TRPV2 IF displayed a strong localization at the
sarcolemma and along the T-tubular network (Figure 2A, left below).
This specific localization was confirmed by a double staining against
the Na+-Ca2+ exchanger (NCX) known to be expressed in the
plasma membrane (Figure 2A, middle and left).23 Western blot analysis
indicated a two-fold TRPV2 overexpression in dystrophic myocytes
(Figure 2B). The specificmembrane bound fraction of TRPV2was deter-
mined using a biotinylation assay and normalized to GAPDH. The
amount of TRPV2 at the plasmamembranewas increased 1.6-fold com-
pared with WT cells (Figure 2C).
3.3 Functional characterization of
sarcolemmal TRPV2 channels
Toassess the functional consequencesof themembrane-specificTRPV2
overexpression inmdx cardiomyocytes,we initially usedpharmacologic-
al tools. TRP channel pharmacology is notoriously unspecific, but the
TRPV2 channels have a peculiar pharmacological profile that sets
themapart frommanyother TRP channels. Contrary tomostTRP chan-
nels, they are not blocked by 2-APB, but become activated (albeit at a
high 2-APB concentration of 500 mM). They are also activated by the
organic anion transporter inhibitor probenecid (Pro, 1 mM). Ruthenium
red (RuR, 40 mM) is an unspecific and tranilast (Tran, 1 mM) a somewhat
more specific inhibitor of TRPV2 channel activity.24–26 To experimen-
tally examine Ca2+ influx without interference from SR Ca2+ release,
mdxmyocytes were preincubatedwith thapsigargin (Tg, 1 mM) and rya-
nodine (Rya, 10 mM) (Figure 3A and B). Subsequently, and prior to the
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actual experiment, several stimulationswith caffeine (Caff, 10 mM)were
applied to completely empty the SR. Both 2-APB and probenecid perfu-
sions induced a Ca2+ influx upon their application (F/F0 of 1.39+0.05
and 1.78+ 0.1, respectively) (Figure 3A and B). ThisCa2+ influxwas sub-
stantially reduced in the presence of the TRPV2 inhibitors (F/F0 of
1.07+ 0.01 for RuR and 1.28+0.05 in the presence of Tran). Taken to-
gether, these findings suggest that in isolated cardiomyocytes, TRPV2
channels indeedmediateCa2+ influx that can be reducedbyTRPV2 inhi-
bitors. With its localization in the sarcolemma of dystrophic myocytes
and its known activation by hypotonicity and stretch-induced mech-
anical stimulation,7,27 a participation of TRPV2 in the excessive cyto-
solic Ca2+ signals could be expected.
3.4 Osmotic stress activates TRPV2
channels
Todeterminewhether TRPV2 channels formpart of SACs in dystrophic
cardiac cells, mdx myocytes were exposed to stress in the presence of
the TRPV2 inhibitor SKF96365 (Figure 3C, left). Data obtained in WT
and mdx myocytes are replotted from Figure 1, for easier comparison.
Figure 3C indicates that after the stress the Ca2+-related fluorescence
was 1.6-fold smaller in the presence of 30 mM SKF96365 (F/F0SKF:
0.93+0.02 compared with untreated mdx cells, 1.41+ 0.09). In add-
itional experiments, we applied the two TRPV2 inhibitors tranilast
and RuR during the osmotic stress (Figure 3D). The Ca2+ signal was
Figure 1 Stress-induced intracellular Ca2+ signals in mdx and wild-type (WT) mouse ventricular cardiomyocytes. (A) Images of Ca2+-related fluo-3
fluorescence obtained in WT (top) and mdx cardiomyocytes (bottom) at the indicated times before (10 s), during (50 s), and after the osmotic stress
(80 and 200 s). Note the more pronounced Ca2+ signals in mdx myocytes. (B) Time course of normalized and averaged Ca2+-related fluorescence,
pooled frommdx (black circles) andWT(greycircles) cardiomyocytes undergoing theosmotic stress protocol. The lineson the top represent theprotocol
bywhich extracellular solutionswere changed. (C) Left, mean values of normalized fluorescence during 40 s after the osmotic shock. Right, estimates of SR
Ca2+ content by 10 mM caffeine stimulation before and after the osmotic challenge. n ¼ 10–17 cells fromN ¼ 2mice forWT; n ¼ 13–14 fromN ¼ 2–4
for mdx. *P, 0.05, **P, 0.01, ns, not significant.
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1.5-fold smaller in the presence of tranilast and 1.6-fold in RuR (F/F0Tran:
0.90+ 0.01 and F/F0RuR: 0.93+ 0.01 compared with untreated mdx
cells, 1.41+0.09). These findings are consistent with an involvement
of TRPV2 channels. However, at present the TRPV2 pharmacology is
not at all specific, as mentioned above.
To allowmore specific conclusions regarding the roleofTRPV2chan-
nels and their identification as subunits of SACs, we used a two-pronged
approach: (i) blockof thechannel porewith antibodies and (ii) ablationof
TRPV2with specific siRNA. First, to achieve specific inhibition of TRPV2
channels,mdx cardiomyocytes were incubated during 24 h with TRPV2
antibodies raised against an extracellular epitope, thereby blocking
the pore to prevent cation influx (Figure 4A).28 Cardiomyocytes
kept in short-term culture undergo substantial dedifferentiation, even
after24 h.Theendsofcardiomyocytes roundupand,most important for
Ca2+ signalling, theT-tubularorganization decreases. To slowdown this
process, we added a low concentration of cytochalasin D (0.5 mM) that
protects cardiomyocytes from the detubulation.29 Compared with un-
treated mdx myocytes, the Ca2+-related fluorescence response was
1.4-fold smaller in cells treated with this antibody (F/F0: 0.88+0.03;
Figure4B).Asnegativecontrol experiments,we incubated cellswith anti-
bodies against an intracellular epitopeof TRPV2 and against TRPC1 (extra-
cellular epitope). These antibodies did not protect the treated mdx cells
from increased Ca2+ signals (F/F0: 1.23+0.09, mdx cells; 1.25+0.07,
anti-TRPC1; 1.09+0.09, anti-TRPV2 intracellular epitope). The SR Ca2+
contentwas not different between the various treatment groups excluding
a possible modification of the cells caused by the short-term cell culture.
Another strategy to specifically remove the function of a particular
protein is to interfere with its expression using siRNA (Figure 5). To
this end, mdx cardiomyocytes were incubated 4 h with siRNA directed
against TRPV2 andmaintained in culture during 24 h.30 Transfectedmdx
Figure 2 Subcellular TRPV2 localization and expression inmdx cardiomyocytes. (A) Immunostaining against an extracellular epitope of TRPV2 (green)
andNCX(red) inWT(above) andmdx (below)cardiomyocytes. (B)Western blot analysis of normalizedTRPV2channels andb-actin expression in cardiac
myocytes. Blot was cut to reduce a wide gap between neighbouring lanes and bands. (C) Sarcolemma-specific TRPV2, GAPDH (control), and P44/P42
MAPK (negative control) expressions (quantified by western blot after biotinylation). P44/P42 MAPK and GAPDH signals were obtained by reprobing
after stripping; the TRPV2 band is contrast enhanced. Cardiomyocytes were isolated from N ¼ 4–7 mdx and WT mice. *P, 0.05, **P, 0.01.
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cardiomyocytes were exposed to osmotic stress (Figure 5A). Ca2+-
related fluorescence was 1.3-fold smaller in cells loaded with TRPV2
siRNA (F/F0: 0.94+ 0.02) compared with the negative control (F/F0:
1.27+ 0.09, Figure 5B). No difference was observed between mdx
cells transfected with scrambled siRNA (negative control) andmdx car-
diomyocytes without transfection and kept in culture during 24 h.
Therefore, the transfection by itself did not interfere with the Ca2+ sig-
nalling response after an osmotic challenge. Ca2+-related fluorescence
Figure 3 Pharmacology of TRPV2 channels. (A) Left, time courses of cytosolic Ca2+ inmdx cardiomyocytes during application of the TRPV2 activator
2-APB (500 mM, at the arrow), with or without the TRPV2 inhibitor ruthenium red (RuR, 40 mM). Cells were pretreated with thapsigargin (Tg, 1 mM),
ryanodine (Rya, 10 mM), and caffeine puffs (Caff, 10 mM) to suppress SR function. Right, mean values of normalized Ca2+-related fluorescence averaged
between 90 and 100 s. (B) Left, time courses of cytosolic Ca2+ inmdxmyocytes with abolished SR, then perfused (arrow) with the TRPV2 activator pro-
benecid (Pro, 1 mM), with or without the TRPV2 inhibitor tranilast (Tran, 1 mM). Right, mean values of normalized Ca2+-related fluorescence averaged
during 20 s at the end of the recording. (C ) and (D) Left, time courses of normalized average fluorescence pooled from inmdx (black circles, C andD),WT
(dark grey circles,C),mdx cardiomyocytes perfusedwith the inhibitors SKF 96365 (30 mM; light grey circles,C), RuR (40 mM; light grey circles,D), andTran
(1 mM; dark grey circles, D). The lines on the top represent the protocol by which extracellular solutions were changed. Time courses of WT and mdx
myocytes are replotted from Figure 1 for easier comparison with the trace obtained from dystrophic cells in the presence of SKF 96365, RuR, and Tran.
(C) and (D) Right, mean values of normalized fluorescence during 40 s after the osmotic shock. n ¼ 8–25, N ¼ 2 for each experiment. **P, 0.01.
Figure4 Stress-induced intracellularCa2+ signals reducedbyTRPV2antibody inmdx ventricular cardiomyocytes. (A)Timecoursesof normalizedCa2+-
related fluorescence pooled frommdx cardiomyocytes pretreated (grey circles) or not (black circles) with an antibody against an extracellular epitope of
TRPV2 (Alomone ACC-39). The lines on the top represent the protocol by which extracellular solutions were changed. (B) Mean values of normalized
fluorescence during 40 s following the osmotic shock in blocking antibodies against an extracellular epitope of TRPV2 and negative control antibodies
(against an intracellular epitope of TRPV2 and against an extracellular epitope of TRPC1). (C) Estimates of SRCa2+ content by 10 mMcaffeine stimulation.
Each experiment n ¼ 4–9 and N ¼ 2. **P, 0.01, ns, not significant.
C. Lorin et al.158
from WT cardiomyocytes (F/F0: 0.98+0.02) was similar to siRNA-
treated mdx cells (F/F0: 0.94+0.02). Among several necessary control
experiments, we verified successful transfection of siRNA into cardiac
myocytes. Figure 5C shows cardiomyocytes that were incubated with
fluorescently labelled siRNA to verify siRNA transfection. In addition,
siRNA transfection and TRPV2 silencing were validated by western blot
analysis and by quantitative RT–PCR (Figure 5D). In siRNA-transfected
cells, TRPV2 expressionwas decreased by 60% compared with the nega-
tive control (using scrambled siRNA). Figure 5E alsohighlights the integrity
of the T-tubular network, as recorded with the fluorescent membrane
dye di-8-ANEPPS. Taken together, these data provide strong evidence
that siRNA-mediated knockdown of TRPV2 normalized the stress-
induced Ca2+ handling in dystrophic cardiomyocytes.
4. Discussion
Dystrophin-deficient cardiomyocytes have an abnormally high mem-
brane fragility, making them sensitive to mechanical stress.9 This loss
Figure5 siRNAablationofTRPV2 inmdx cardiomyocytes. (A) Timecoursesof normalizedCa2+-relatedfluorescencepooled frommdxmyocytes trans-
fectedwith siRNAdirectedagainstTRPV2 (grey circles) or scrambled siRNAas anegative control (black circles). Lineon the top represents theprotocol by
which extracellular solutions were changed. (B) Mean values of normalized fluorescence during 40 s after the osmotic shock obtained from untransfected
mdxmyocytes,mdx cells transfectedwith scrambled siRNA,mdx cells transfectedwith siRNA against TRPV2 andWTcardiomyocytes.WTdata replotted
for comparison. (C) Fluorescence and transmission images ofmdx ventricular cardiomyocytes showing successful transfection with fluorescently labelled
siRNA. (D) Statistical analysis of reduced protein and mRNA expressions by western blot (left and inset) and by RT–PCR (right) inmdx cardiomyocytes
after transfection with siRNA directed against TRPV2. (E) Confocal images of T-tubular network with di-8ANEPPS membrane staining after transfection
with scrambled siRNA and siRNA against TRPV2, respectively. n ¼ 7–11, N ¼ 4–8. *P, 0.05, **P, 0.01, ns, not significant.
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of membrane integrity leads to an increased permeability that allows an
abnormal stress-induced influx of extracellular Ca2+, presumably via
SACs and membrane microruptures.
4.1 The two-hit hypothesis of dystrophic
cardiomyopathy
Even though the lackof functional dystrophinprotein has been identified
as the cause formany forms of this disease, themechanism(s) linking the
absence of this cytoskeletal protein with the observed cellular damage
remain poorly understood. Several versions of a ‘two-hit hypothesis’
have been proposed as pathomechanisms of muscular dystrophies and
dystrophic cardiomyopathies.31 These hypotheses postulate a com-
bined effect of abnormal Ca2+ signals, both from sarcolemmal influx
and SR leak, and oxidative stress. In normal muscle, the neuronal nitric
oxide synthase (nNOS) is a member of the DGC and localized at the
sarcolemma. NO can protect cells from stronger oxidative damage by
playing an antioxidant role and by inhibiting NADPH oxidases, the
major sources of reactive oxygen species (ROS).32 In dystrophic myo-
cytes, nNOS is down-regulated, contributing to an enhanced generation
of ROS.33 In these cells, the abnormal Ca2+ influx and release further
stimulate ROS production by mitochondria andNADPH oxidases, par-
ticularly after mechanical stress.15,34 As a consequence, these ROS may
lead to further Ca2+ influx by increasing themembrane permeability via
lipid peroxidation and to additional SR release by oxidation of several
proteins.35 Thus, in cardiac muscle, the Ca2+ signalling pathology
defined by the two-hit hypothesis has two components: (i) hypersensi-
tive Ca2+-induced Ca2+ release from the SR (e.g. as sparks or invisible
leak), presumably as a result of post-translational modifications of the
RyRs (e.g. oxidation, phosphorylation, or hypernitrosylation).16,36–39
(ii) Abnormally high Ca2+ influx across the fragile sarcolemma, particu-
larly after mechanical stress.5,10,12,40 The relative importance of
these two mechanisms seems to change during the progression of the
disease, with the SR leak becoming more and more prominent.36
Overall, the two-hit mechanism creates an endless loop of abnormal
Ca2+ entry and oxidative damage that may culminate in activation of
Ca2+-dependent proteases and apoptotic or necrotic cell death. In prin-
ciple, both mechanisms could offer multiple possibilities and targets for
future pharmacological treatments.
4.2 Ca21 influx via stretch-activated
membrane channels
In the present study, we focused on one of the putative pathomechan-
isms involved in abnormal Ca2+ influx: stretch-activated membrane
channels (SACs). The molecular identity of SACs involved in dystrophy
is presently unknown.However, previous studies haveproposed several
candidates as potential SAC subunits inmdx cardiomyocytes to explain
the elevated Ca2+ entry during mechanical stress, such as transient re-
ceptor potential canonical channel 1 (TRPC1) and 6 (TRPC6).19,41
Others reportedTRPV2channels toplayan important role indystrophic
skeletalmuscle fibres.17,20 Interestingly, overexpressionofTRPC3chan-
nels resulted in a dystrophy-like phenotype.42 Most of these TRP chan-
nels form cation channels that are permeable to monovalent and
divalent ions, thus carrying entry of both Na+ and Ca2+.43
4.3 Identification of TRP channels
contributing to SACs
Unfortunately, the pharmacological tools available to identify particular
TRP channels as components of SACs are very unspecific. Most of those
compounds affect several or many TRP channels in the same range of
concentrations. Therefore, we applied a multipronged approach as
the strategy to define the role of TRP channels in the abnormal Ca2+
signals we observed. Using several available but unspecific pharmaco-
logical tools, we established a pharmacological profile of the abnormal
Ca2+ signals, as detailed below. This pharmacological profile turned
out to be quite unique and suggested that TRPV2 channels might be
involved. As a second approach, we examined the TRPV2 expression
and cellular distribution in normal and dystrophin-deficient cardiomyo-
cytes. These results indicated that TRPV2 channel might indeed play a
role in thediseasephenotype. Finally,weusedmore specific tools to pin-
point TRPV2 as a component of SACs in dystrophic myocytes. This
included the use of blocking antibodies raised against an extracellular
epitope of the channels and the application of siRNA technology to
ablate the TRPV2 protein.
4.4 TRPV2 protein is overexpressed in
dystrophic cardiomyocytes
Histologically, TRPV2 proteins have been identified in various tissues
andorgans suchasbrain, lungs, skeletal, andcardiacmuscle.44Their func-
tion is not yet well elucidated, but previous studies highlighted their in-
volvement in sensation of excessive heat, osmosensory mechanisms,
insulin exocytosis, and cardiovascular functions.7,27,45,46 Under physio-
logical conditions, immunoelectron microscopy studies revealed a
TRPV2 localization in intracellularmembrane compartments, specifical-
ly in the endoplasmic reticulum.Nevertheless, upon specific stimulation,
TRPV2 proteins are translocated to the sarcolemma to mediate an
extracellular Ca2+ influx.47 It has been proposed that the translocation
of TRPV2 could resemble that of glucose transporter 4 (GLUT4).
GLUT4 is an insulin-regulated glucose transporter translocated from
an intracellular storage to theplasmamembraneupon insulin stimulation
in adipocytes and in skeletal muscle fibres. Upon IGF-1 stimulation,
TRPV2 channels are targeted to the sarcolemma via the phosphatidyli-
nositol 3-kinase (PI3K) pathways.46,48 Recently, new insight about this
cation channel has been obtained in several pathological conditions. In
dystrophic skeletal muscle fibres andmyotubes in culture, TRPV2 chan-
nelswereobserved tobe translocated fromthe intracellular space to the
sarcolemma.17,20,49,50 In agreement with these observations, in our
study, mdx cardiomyocytes displayed a strong TRPV2 localization at
the sarcolemma and along the T-tubular network, compared with WT
cells.Moreover,we found that this abnormal translocation is accompan-
ied by a TRPV2 overexpression, particularly at the sarcolemma, as sug-
gested by biotinylation assays. Together, the elevated expression and
translocation of TRPV2 channels in dystrophic cardiomyocytes are
clearly consistent with their possible role in SACs and, further, suggest
a stronger activity of TRPV2 in these cells.
4.5 TRPV2 as potential components of SACs
is supported by unspecific TRP channel
pharmacology
To assess the TRPV2 function at the plasma membrane of dystrophic
myocytes, a pharmacological approach was used. As mentioned
above, a known problem in the field of TRP channel research is the
lack of highly specific pharmacological tools.51 Furthermore, the effi-
ciency of many compounds depends on the cell type and even the
species.47 Inmany cases, several unspecific compounds are used experi-
mentally to block various TRP channels, such as ruthenium red, 2-APB,
and SKF96365. For few channels, some specific agonists are available,
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such as capsaicin for TRPV1 channels. Another promising strategy is to
apply a compound that activates some TRP channels but block others.
2-APB, which is a blocker of many TRP channels, was the first activator
identified for some TRPV channels, including TRPV2, in HEK293 cells.47
Indeed, in our experiments with cardiomyocytes pretreated with
thapsigargin and ryanodine (to eliminate SR function), the application
of 2-APB elicited Ca2+ influx from the extracellular space that could
be inhibited with ruthenium red. Consistent with a role of TRPV2 in
Ca2+ influx, the blocker SKF96365 also suppressed the stress-induced
Ca2+ signals.26 There are twopharmacological TRPV2modulators, pro-
benecid and tranilast (activator and inhibitor, respectively), that have
been reported to exhibit somewhat better specificity for TRPV2 chan-
nels. Probenecid was initially synthesized to reduce the renal excretion
of antibiotics, particularly penicillin, and recently, it has been identified as
an agonist of TRPV2.52,53 Tranilast is clinically used as an antiallergic drug
and experimentally as a TRPV2 antagonist.46 Both compounds changed
Ca2+ influx in dystrophicmyocytes with eliminated SR function in a way
thatwas perfectly consistentwithTRPV2underlying this kindof influx. In
summary, the analysis of the pharmacological profile revealed by our
experiments allowed us to consider a pathological TRPV2 function in
mdx cardiomyocytes.
4.6 Specific inhibition of TRPV2 protects
dystrophic myocytes from abnormal Ca21
signals
To specifically probe whether TRPV2 channels are responsible for the
Ca2+ increase after an osmotic shock in dystrophic myocytes, we
applied an antibody raised against an extracellular epitope of the
channel. If the channel pores are indeed blocked by these antibodies,
this strategy suppresses the TRPV2 protein function and Ca2+ can no
longer enter the cytoplasm. However, the specificity of blocking anti-
bodies has been challenged in different studies and may depend on a
variety of parameters such as the type of experiments (western blot,
immunocytochemistry), species (rat, mouse), and type of antibodies
(polyclonal, monoclonal). Therefore, we carried out several control
experiments using other antibodies during the osmotic stress. As nega-
tive control experiments, we used antibodies raised against an intracel-
lular epitope of the TRPV2 channel and against an extracellular epitope
of TRPC1. In these experiments, we did not observe any inhibition of
the TRPV2 function since the Ca2+-related fluorescence in mdx cells
increased in the samemanner aswithout antibodies. Therefore,we con-
cluded that incubation with a TRPV2 antibody against an extracellular
epitope eliminated the stress-induced signals by specifically blocking
TRPV2.
Another approach to specifically interfere with the function of the
channel is the use of siRNA against TRPV2 mRNA. After entering the
cell by transfection, this specific siRNAbinds theTRPV2mRNAby com-
plementarity. This binding prevents the TRPV2 mRNA translation after
transcription by specific destruction of the mRNA by exonucleases,
essentially preventing the protein synthesis. After incubation of mdx
myocytes with siRNA, western blot and quantitative RT–PCR experi-
ments confirmed the decrease of the expression of TRPV2 protein
(down to 40%) compared with dystrophic cells transfected with
scrambled siRNA. Myocytes were maintained in short-term primary
culture for 24 h before carrying out the experiments to allow for
the normal degradation of pre-existing TRPV2 protein. The results
showed that the Ca2+-related fluorescence after an osmotic challenge
in mdx myocytes transfected with anti-TRPV2 siRNA was comparable
to WT cells, while mdx myocytes transfected with scrambled siRNA
behaved like untransfected dystrophic cells.
5. Conclusion
Taken together, our observations indicate a major role of TRPV2 chan-
nels in the cardiac dystrophic Ca2+ signalling pathology and provide
compelling evidence that the TRPV2 proteins form a subunit of SACs.
5.1 TRPV2 channels and dystrophinopathies
Dystrophinopathies give rise to a wide spectrum of muscle diseases.
Most forms include cardiac muscle participation. The most severe is
DMD, characterizedby the absenceof dystrophin. Beckermuscular dys-
trophy results in a milder phenotype since dystrophin is produced but
only partly functional. InX-linked cardiomyopathy (XLDCM), dystroph-
in is absentonly in thecardiacmuscle.These threedystrophinopathies all
progress into a DCM.54 As mentioned above, the two-hit hypothesis
postulates a major pathological role for abnormal Ca2+ influx across
the sarcolemma as one of the main pathomechanisms. Our study
reveals that TRPV2 proteins are abnormally recruited and activated in
dystrophic cardiac myocytes. Thus, the TRPV2 proteins, their function,
and translocation pathway could be relevant targets for future pharma-
cological treatments of these and related pathologies.
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